High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
复制标题
高水平的血清磷脂酰肌醇蛋白聚糖-1 (glypican-1) 表明胰腺导管腺癌的预后不良。
DOI：
10.1002/cam4.1833
复制
发表时间：
2018-11
期刊：
影响因子：
4
通讯作者：
Han SX
中科院分区：
文献类型：
--
作者：
Zhou CY;Dong YP;Sun X;Sui X;Zhu H;Zhao YQ;Zhang YY;Mason C;Zhu Q;Han SX
碳水化合物抗原19 - 9（CA19 - 9）未能证明早期检测胰腺导管腺癌（PDAC）的预测价值。磷脂酰肌醇蛋白聚糖-1（GPC1+）外泌体可以作为一种非侵入性诊断工具来检测早期PDAC。因此，有必要探讨血清GPC1水平，并确定血清GPC1是否可作为PDAC患者的新生物标志物。从156名PDAC患者、199名非癌症对照和240名其他癌症患者中采集血液样本。通过酶联免疫吸附试验（ELISA）检查GPC1的血清学水平。最后，对156例PDAC患者进行了5年随访，以评估血清GPC1水平与总生存期之间的相关性。结果表明，PDAC患者血清GPC1和CA19 - 9水平均高于对照组（P <0.05）。PDAC患者血清GPC1水平与胆囊癌（P <0.001）、结直肠癌（P <0.001）、胃癌（P <0.001）、前列腺癌（P <0.001）比较差异有统计学意义，而与肝细胞癌（P = 0.395）、胆管细胞癌（P = 0.724）比较差异无统计学意义。受试者工作特征曲线（ROC）分析显示，血清CA19 - 9在区分PDAC患者和对照组方面显著优于血清GPC1（AUC，95% CI：分别为0.908，0.868 - 0.947 vs 0.795，0.749 - 0.841）。血清GPC1不能作为PDAC患者的血清诊断生物标志物。术后2d血清GPC1水平下降（P = 0.001），与健康对照组比较差异无统计学意义（P = 0.381）。与血清GPC1水平低的患者相比，血清GPC1水平高的患者的总生存率较短（log-rank = 5.16，P = 0.023）。总之，结果表明，高水平的血清GPC1预测PDAC患者的预后不良。血清GPC1可能是PDAC患者的一个预后指标。
Carbohydrate antigen 19‐9 (CA19‐9) fails to demonstrate the predictive value for early detection pancreatic ductal adenocarcinoma (PDAC). Glypican‐1 (GPC1+) exosomes may serve as a noninvasive diagnostic tool to detect early stages of PDAC. Therefore, it is necessary to explore the serum GPC1 levels and determine whether serum GPC1 serves as a novel biomarker for PDAC patients. Blood samples were collected from 156 patients with PDAC, 199 non‐cancer controls, and 240 patients with other cancers. Serological levels of GPC1 were examined by enzyme‐linked immunosorbent assay (ELISA). Finally, a 5‐year follow‐up was monitored to evaluate the correlation between serum GPC1 levels and overall survival in 156 patients with PDAC. The results suggested that levels of serum GPC1 and CA19‐9 were higher in PDAC patients than that of controls (P < 0.05). Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724). Receiver operating characteristic curve (ROC) analysis showed that serum CA19‐9 was significantly better than serum GPC1 in distinguishing PDAC patients from the controls (AUC, 95% CI: 0.908, 0.868‐0.947 vs 0.795, 0.749‐0.841, respectively). The serum GPC1 cannot be used as a serum diagnostic biomarker for PDAC patients. The level of serum GPC1 decreased 2 days after surgery (P = 0.001), which were not different from serum GPC1 levels in healthy control (P = 0.381). The overall survival rate was shorter in patients with high levels of serum GPC1 compared to those with low levels of serum GPC1 (log‐rank = 5.16, P = 0.023). Taken together, the results indicate that high levels of serum GPC1 predict poor prognosis in PDAC patients. Serum GPC1 may be a prognosis factor for PDAC patients.
登录
查看更多内容
DOI：
10.1038/ajg.2016.482
发表时间：
2017-01
期刊：
The American journal of gastroenterology
影响因子：
--
作者：
Kaur S;Smith LM;Patel A;Menning M;Watley DC;Malik SS;Krishn SR;Mallya K;Aithal A;Sasson AR;Johansson SL;Jain M;Singh S;Guha S;Are C;Raimondo M;Hollingsworth MA;Brand RE;Batra SK
通讯作者：
Batra SK
影响因子：
6.4
作者：
Duell EJ;Lujan-Barroso L;Sala N;Deitz McElyea S;Overvad K;Tjonneland A;Olsen A;Weiderpass E;Busund LT;Moi L;Muller D;Vineis P;Aune D;Matullo G;Naccarati A;Panico S;Tagliabue G;Tumino R;Palli D;Kaaks R;Katzke VA;Boeing H;Bueno-de-Mesquita HBA;Peeters PH;Trichopoulou A;Lagiou P;Kotanidou A;Travis RC;Wareham N;Khaw KT;Ramon Quiros J;Rodríguez-Barranco M;Dorronsoro M;Chirlaque MD;Ardanaz E;Severi G;Boutron-Ruault MC;Rebours V;Brennan P;Gunter M;Scelo G;Cote G;Sherman S;Korc M
通讯作者：
Korc M
影响因子：
8.8
作者：
Hara H;Takahashi T;Serada S;Fujimoto M;Ohkawara T;Nakatsuka R;Harada E;Nishigaki T;Takahashi Y;Nojima S;Miyazaki Y;Makino T;Kurokawa Y;Yamasaki M;Miyata H;Nakajima K;Takiguchi S;Morii E;Mori M;Doki Y;Naka T
通讯作者：
Naka T
DOI：
10.1158/1078-0432.ccr-14-0289
发表时间：
2014-11-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chan A;Prassas I;Dimitromanolakis A;Brand RE;Serra S;Diamandis EP;Blasutig IM
通讯作者：
Blasutig IM
影响因子：
6
作者：
Su, Gui;Meyer, Kristy;Friedl, Andreas
通讯作者：
Friedl, Andreas